https://www.sciencedaily.com/releases/2020/06/200609130006.htm

The researchers, whose findings appear June 9 in the journal BMJ Open, analyzed the 201 clinical trials for drugs or plasma that, as of March 26, had been registered in the U.S. under ClinicalTrials.gov and in the international clinical trials registry maintained by the World Health Organization (WHO). Of the trials analyzed in this early snapshot, 100 (49.8 percent) were registered in China and 78 (37.8 percent) in the U.S. The majority of trials in the U.S. clinical trials registry were registered from international researchers. Among the 201 trials analyzed, 126 were recruiting participants from China, 31 from Europe, 14 from the U.S.

The researchers found that many of the trials lacked key features needed to optimize their scientific value such as the use of control groups and patient and clinician blinding.